The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview
Abstract
The popular dance drug ecstasy (3,4-methylenedioxymethamphetamine -- MDMA) is neurotoxic upon central serotonergic neurons in laboratory animals and possibly also in humans. In recent years, several studies reported alterations of serotonergic transmission and neuropsychiatric abnormalities in ecstasy users which might be related to MDMA-induced neurotoxic brain damage. To date, the most consistent .ndings associate subtle cognitive, particularly memory, de.cits with heavy ecstasy use. However, most studies have important inherent methodological problems. One of the most serious confounds is the widespread pattern of polydrug use which makes it dif.cult to relate the .ndings in user populations to one speci.c drug. The present paper represents a brief overview on this issue. The most commonly co-used substances are alcohol, cannabis and stimulants (amphetamines and cocaine). Stimulants are also neurotoxic upon both serotonergic and dopaminergic neurons. Hence, they may act synergistically with MDMA and enhance its long-term adverse effects. The interactions between MDMA and cannabis use may be more complex: cannabis use is a wellrecognized risk factor for neuropsychiatric disorders and it was shown to contribute to psychological problems and cognitive failures in ecstasy users. However, at the cellular level, cannabinoids have neuroprotective actions and they were shown to (partially) block MDMA-induced neurotoxicity in laboratory animals. In future, longitudinal and prospective research designs should hopefully lead to a better understanding of the relation between drug use and subclinical psychological symptoms or neurocognitive failures and, also, of questions around interactions between the various substances of abuse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
Cannabis use and mental health in young people: cohort study.
Patton, G. C., Coffey, C., Carlin, J. B., Degenhardt, L., Lynskey, M., & Hall, W. (2002) · BMJ · doi:10.1136/bmj.325.7374.1195 · Cited by 997
Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850 · cited 1×
“…properties of cannabinoids at the cellular level as well as neuroprotection in a variety of models of neuronal injury, both in vitro and in vivo (e.g. Hampson et al., 1998; Hampson and Grimaldi, 2001; Grundy et al., 2001; Mechoulam et al., 2002; van der Stelt et al., 2002; van der Stelt, 2005).”
BackgroundMacleod, J., Oakes, R., Copello, A., Crome, I., Egger, M., Hickman, M., Oppenkowski, T., Stokes-Lampard, H., & Smith, G. D. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16200-4 · Cited by 639
McCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., & Ricaurte, G. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-20-08417.1998 · Cited by 602
Exploring the association between cannabis use and depression.
Degenhardt, L., Hall, W., & Lynskey, M. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00437.x · Cited by 587 · cited 1×
“Regular use of cannabis is a well-recognized risk factor for psychiatric disorders such as depression, psychosis and amotivation (Patton et al., 2002; Degenhardt et al., 2003; Hall et al., 2004; Macleod et al., 2004).”
Background(±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical Studies
McCann, U. D., Eligulashvili, V., & Ricaurte, G. A. (2000) · Neuropsychobiology · doi:10.1159/000026665 · Cited by 190 · cited 2×
“Current evidence suggests that MDMA may be also neurotoxic in humans and may be associated with alterations in psychological functions, cognition or other brain functions (e.g. McCann et al., 1998a, 2000; Reneman et al., 2001).”
BackgroundImpact of Cannabis Use on Brain Function in Adolescents
JACOBSEN, L. K., MENCL, W. E., WESTERVELD, M., & PUGH, K. R. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1308.053 · Cited by 128
Cited by
Toxicity of amphetamines: an update
Carvalho, M., Carmo, H., Costa, V. M., Capela, J. P., Pontes, H., Remião, F., Carvalho, F., & Bastos, M. D. L. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0815-5 · Cited by 431
The Chronic Effects of Cannabis on Memory in Humans: A Review
Solowij, N., & Battisti, R. (2008) · Current Drug Abuse Reviewse · doi:10.2174/1874473710801010081 · Cited by 380
Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine
Dunlap, L. E., Andrews, A. M., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00155 · Cited by 106
The neuropsychology of ecstasy (MDMA) use: a quantitative review.
Zakzanis, K. K., Campbell, Z., & Jovanovski, D. (2007) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.873 · Cited by 87
Metadata
- Authors
- Gouzoulis-Mayfrank, E., & Daumann, J.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2006-03
- Volume
- 20
- Issue
- 2
- Pages
- 188-193
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1993455459
- Cited by
- 179
- References
- 8
- FWCI
- 23.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. https://app.cochat.ai/papers/10.1177/0269881106059939
- The paper
- Gouzoulis-Mayfrank, E., & Daumann, J. (2006). The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. Journal of Psychopharmacology. https://doi.org/10.1177/0269881106059939
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.